NO20063207L - Process for improving the efficacy of therapeutic radioactive drugs - Google Patents

Process for improving the efficacy of therapeutic radioactive drugs

Info

Publication number
NO20063207L
NO20063207L NO20063207A NO20063207A NO20063207L NO 20063207 L NO20063207 L NO 20063207L NO 20063207 A NO20063207 A NO 20063207A NO 20063207 A NO20063207 A NO 20063207A NO 20063207 L NO20063207 L NO 20063207L
Authority
NO
Norway
Prior art keywords
efficacy
improving
drug
radiolabelled
radioactive drugs
Prior art date
Application number
NO20063207A
Other languages
Norwegian (no)
Inventor
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20063207L publication Critical patent/NO20063207L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Radiomerkede legemidler og fremgangsmåter for å forbedre effektiviteten av dem ved å anvende en radiosensitiviserer slik at derme enten er en del av det radiomerkede legemiddelet ved å anbringe den direkte i det radiomerkede legemiddelet, eller fremstille en blanding av det radiomerkede legemiddelet og en analog av legemiddelet med radiosensitivisereren knyttet til legemiddelet i stedet for radiomerkingen.Radiolabelled drugs and methods for improving their efficacy by using a radiosensitizer so that they are either part of the radiolabelled drug by placing it directly in the radiolabelled drug or preparing a mixture of the radiolabelled drug and an analogue of the drug with the radio sensitizer attached to the drug instead of the radiolabeling.

NO20063207A 2003-12-11 2006-07-10 Process for improving the efficacy of therapeutic radioactive drugs NO20063207L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52847303P 2003-12-11 2003-12-11
PCT/IB2004/004428 WO2005056058A2 (en) 2003-12-11 2004-12-13 Radiosensitizer conjugate to improve the efficacy of radiolabeled drugs

Publications (1)

Publication Number Publication Date
NO20063207L true NO20063207L (en) 2006-07-10

Family

ID=34676848

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063207A NO20063207L (en) 2003-12-11 2006-07-10 Process for improving the efficacy of therapeutic radioactive drugs

Country Status (14)

Country Link
EP (1) EP1691838A2 (en)
JP (1) JP2007528874A (en)
KR (1) KR20060118542A (en)
CN (1) CN101031319A (en)
AU (1) AU2004296621A1 (en)
BR (1) BRPI0417517A (en)
CA (1) CA2546057A1 (en)
CR (1) CR8439A (en)
EC (1) ECSP066618A (en)
IL (1) IL175674A0 (en)
MX (1) MXPA06006683A (en)
NO (1) NO20063207L (en)
RU (1) RU2006124510A (en)
WO (1) WO2005056058A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568453B (en) * 2011-11-22 2017-02-01 原創生醫股份有限公司 A drug carrier with chelating complex micelles and the application thereof
CN106975078B (en) * 2017-03-31 2020-11-10 国家纳米科学中心 Application of nano material containing gadolinium polytungstate as sensitizer
WO2024013272A1 (en) * 2022-07-13 2024-01-18 Universite De Montpellier Combined therapy with nanoparticles and radiopharmaceuticals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022404A1 (en) * 1999-01-25 2002-09-04 Photogen Inc METHOD AND AGENTS FOR IMPROVED RADIATION THERAPY
WO2001072958A2 (en) * 2000-03-28 2001-10-04 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
BR0206985A (en) * 2001-01-29 2005-04-19 Idec Pharma Corp Modified Antibodies and Methods of Use
EP1534336A4 (en) * 2002-08-15 2005-12-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
JP2007528874A (en) 2007-10-18
EP1691838A2 (en) 2006-08-23
AU2004296621A1 (en) 2005-06-23
KR20060118542A (en) 2006-11-23
MXPA06006683A (en) 2006-08-11
WO2005056058A2 (en) 2005-06-23
BRPI0417517A (en) 2007-03-06
ECSP066618A (en) 2006-10-25
IL175674A0 (en) 2006-09-05
RU2006124510A (en) 2008-01-20
WO2005056058A3 (en) 2006-04-13
CR8439A (en) 2006-12-07
CN101031319A (en) 2007-09-05
CA2546057A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
TW200738228A (en) Neramexane modified release matrix tablet
NO20055863L (en) W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
NO20060446L (en) Tricyclic delta opioid modulators
NO20073959L (en) Quinazoline derivative, method of preparation and use thereof for inhibiting cancer cell growth
ECSP055701A (en) NEW DERIVATIVES OF PYRIMIDINAMIDE AND THE USE OF THE SAME
HK1072180A1 (en) Combinations for treating multiple myeloma
DK1636236T3 (en) Pyrazolo-quinazoline derivatives, a process for their preparation, and their use as kinase inhibitors
DE602005017895D1 (en) PYRAZOLAMIDE DERIVATIVES, COMPOSITIONS AND METHODS OF APPLYING THESE COMPOUNDS
NO20055173L (en) Pharmaceutical combination combination comprising modafinil and another drug
DK1781277T3 (en) Combination composition comprising Ibuprofen and Paracetamol
NO20080969L (en) 1,2-diarylimidazoles for use as CBI modulators
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MX2021015352A (en) Methods of treating fabry disease in patients having renal impairment.
DK1594885T3 (en) Drug for growth inhibition of tumors
NO20063207L (en) Process for improving the efficacy of therapeutic radioactive drugs
HK1081880A1 (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
NO20052172L (en) 4-aminopiperidine derivatives, process for their preparation and their use as drugs
DE60124144D1 (en) PHARMACEUTICAL COMPOSITIONS FOR REINFORCING THE MEDICINAL EFFECTS
AR025060A1 (en) PHARMACEUTICAL FORMULATIONS IN HYDROXYPROPILMETILCELLULOSE CAPSULES
JP2020536923A5 (en)
ECSP056190A (en) USEFUL COMPOUNDS IN ALZHEIMER'S DISEASE THERAPY AND FORMULATIONS CONTAINING THEM
NO20083784L (en) Fresh citrate salt of an indole derivative and its pharmaceutical use
NO20054723L (en) Treatment of proliferative diseases with epophilone derivatives and radiation
NO20075508L (en) Stable Soporphine Preparations and Administration

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application